Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.76 USD | -1.69% | -3.92% | -41.12% |
04-25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
04-25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.12% | 781M | |
+4.38% | 106B | |
+7.02% | 23.47B | |
-14.28% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.24% | 16.78B | |
+7.15% | 14.41B | |
+37.57% | 12.86B | |
+317.95% | 8.78B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- RBC Raises PT on Sage Therapeutics to $26 From $21, Says Early Metrics From Zurzuvae Launch Suggest Promising Signs; Keeps Sector Perform, Speculative Risk